generics
-
First floor
Price of medicines: a reply to the Director of AIFA. With the fetish of transparency, the hedging difficulties of a State with delusions of omnipotence are unloaded on the sector
The medicines market is heavily regulated. Even before some specific strategies to contain pharmaceutical expenditure, such as…
Leggi » -
News
Tuscany Regional Administrative Court. Biologics and biosimilars are not identical. Automatic substitution is not allowed. Regional Resolution 194: excess of power and incompetence
Ancora una volta l’oggetto del contenzioso sono farmaci biologici e l’orientamento delle scelte prescrittive. I giudici accolgono il rilievo di…
Leggi » -
News
EMA communication on sartans: reviewing production processes to avoid probable carcinogenic pollutants
Companies that manufacture sartan blood pressure medications (also known as angiotensin II receptor blockers)…
Leggi » -
News
Chiazzese (M5S): what does the government intend to do to increase the sales of generic drugs? Minister Grillo: "strengthening information to increase its use" Editor's note
For information, we report the question below Oral answer question 3-00175 presented by CHIAZZESE Giuseppe Tuesday 18 September 2018, session…
Leggi » -
News
USA. Investors in Big Pharma are demanding higher profits. The financial limits of biotechnology and the pitfalls of generics
Big Pharma Tackles Curse of Billionaire Blockbuster Investors Demand Today's Extraordinarily Lucrative Drugs Have a…
Leggi » -
News
The UK Regulatory Agency (MHRA) is recalling batches of the generic ibersartan as a precaution
Il farmaco ibersartan per la pressione e per il cuore richiamati da MHR Le farmacie di tutto il Regno Unito…
Leggi » -
News
Assogenerics. Payback: Protect all pharmaceutical SMEs
“Salutiamo la riforma del sistema del pay back, introdotta con la legge di bilancio che, dopo molti anni di riflessioni,…
Leggi » -
News
Società Italiana Rheumatologia appeals to the TAR against the purchase of five regions of a single biosimilar. Prescriptive freedom is not guaranteed
SIR: “garantire sempre la liberta’ prescrittiva del medico e la continuita’ terapeutica del paziente reumatologico” La Società Scientifica ha presentato…
Leggi » -
News
The Association of Doctors Against Biosimilars. Numerous adverse events reported to Aifa after switch
La società scientifica contro i biosimilari. Una sigla dei camici bianchi si sta impegnando con forza contro la sostituzione dell’originator…
Leggi » -
News
EMA. Valsartan: after the pollutants of medicines produced in China found other impurities in the class of sartans produced in India
L’Agenzia Europea dei Medicinali (EMA) ha esteso la revisione delle impurezze rilevate nel valsartan a seguito della rilevazione di livelli…
Leggi »